Search Results 1821-1830 of 16340 for Epilepsy (Partial Onset)

1. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor - Mayo Clinic

   The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.

2. A Study of Lenalidomide Combined with a Standard Chemotherapy for Treating Patients with Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma - Mayo Clinic

   Expected survival duration of > 3 months; Karnofsky performance status > 70 ... Prothrombin time (PT), international normalized ratio (INR), and partial ...

3. Peripheral nerve tumors - Doctors and departments - Mayo Clinic

   ... epilepsy, Brain tumor-associated epilepsy. Show more areas of focus for Kaisorn L. Chaichana, M.D.. Victoria E. Clark, M.D., Ph ...

4. Esketamine (nasal route) - Side effects & dosage - Mayo Clinic

   Esketamine nasal spray is also used together with an antidepressant taken by mouth, to treat depressive symptoms in patients with major depressive disorder (MDD) ...

5. Neurology - Clinical trials

   The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure ...

6. Congenital Disorders Clinical Trials - Mayo Clinic Research

   The objectives of this study are to collect data on survival of pediatric patients with early onset of either GM1 gangliosidosis, GM2 gangliosidoses, or GD2 ...

7. Pilot and Feasibility Program - Mayo Clinic Research

   Supports both new investigators beginning their careers in digestive diseases research and innovative proposals from experienced investigators who plan to ...

8. Traumatic Injury Clinical Trials - Mayo Clinic Research

   To determine the incidence of subclinical electrographic seizures and electrographic status epilepticus in children admitted to the PICU for head trauma, ...

9. Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients - Mayo Clinic

   ... duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. Has known psychiatric or ...

10. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

    Confirmed COVID-19: the Baseline visit must be at least 14 days from onset of signs/symptoms or positive SARS-CoV-2 test, symptomatic subjects must have ...